Nuvectis Pharma, Inc. (NVCT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$18.47-4.50%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · NVCT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -47.2% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers · Company calendar date is not available
NVCT — earnings miss
Dated 2026-11-04
Results of Operations and Financial Condition. On November 4, 2026, Nuvectis Pharma, Inc. issued a press release to provide a corporate update and to announce its financial results for the third quarter ended September 30, 2026. A copy of such press release is being furnished as Exhibit 99.1 to this report. The information, including Exhibit 99.1, in this Form 8-K is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended,…
Why it matters: The report can show whether the planned FDA steps are on time. Delays in both programs would slow the new pipeline plan.
Watch forOn November 3, Nuvectis confirms the NXP100 and NXP200 IND filings remain on track for 4Q2026.
Also watch forOn November 3, Nuvectis reports either IND filing has slipped beyond 4Q2026 or faces an FDA hold.
Why it matters: The company raised $115 million and said its cash runway reaches into 1H 2029. ATM share sales may add cash, but they also increase the share count.
Watch forA filing shows no ATM shares sold, and management still reports cash runway into 1H 2029.
Also watch forA filing shows ATM share sales, and the share count rises while management reports a shorter cash runway.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.4% | How much price usually moves either way. |
| Bad day | $597 loss on $10,000 · 6.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,691 loss on $10,000 · 36.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.